{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":7,"podcast":6,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03971474\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03971474","nct_id":"NCT03971474","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03971474. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive docetaxel IV over 10-30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 or ramucirumab IV over 60 minutes and docetaxel IV over 10-30 minutes on day 1. Patients with non-squamous NSCLC receiving docetaxel and gemcitabine hydrochloride, also receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm B (ramucirumab, pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2024-01-01","type":"ACTUAL"},"conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":{"count":166,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Docetaxel","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Gemcitabine Hydrochloride","type":"DRUG"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Pemetrexed Disodium","type":"DRUG"},{"name":"Ramucirumab","type":"BIOLOGICAL"}],"last_update":"2024-09-03","lead_sponsor":"SWOG Cancer Research Network","official_title":"A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-04-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"From date of registration to a maximum of 2 years and 11 months or death"}],"references":[],"start_date":{"date":"2019-05-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","url":"https://clinicaltrials.gov/study/NCT03971474"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03971474"}